184 related articles for article (PubMed ID: 10426790)
1. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.
Aparicio T; Kermorgant S; Dessirier V; Lewin MJ; Lehy T
Carcinogenesis; 1999 Aug; 20(8):1445-51. PubMed ID: 10426790
[TBL] [Abstract][Full Text] [Related]
2. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Low JA; Johnson MD; Bone EA; Dickson RB
Clin Cancer Res; 1996 Jul; 2(7):1207-14. PubMed ID: 9816289
[TBL] [Abstract][Full Text] [Related]
3. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
Sledge GW; Qulali M; Goulet R; Bone EA; Fife R
J Natl Cancer Inst; 1995 Oct; 87(20):1546-50. PubMed ID: 7563189
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models.
Watson SA; Morris TM; Robinson G; Crimmin MJ; Brown PD; Hardcastle JD
Cancer Res; 1995 Aug; 55(16):3629-33. PubMed ID: 7627972
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
7. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control.
Jimenez RE; Hartwig W; Antoniu BA; Compton CC; Warshaw AL; Fernández-Del Castillo C
Ann Surg; 2000 May; 231(5):644-54. PubMed ID: 10767785
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
Watson SA; Morris TM; Parsons SL; Steele RJ; Brown PD
Br J Cancer; 1996 Nov; 74(9):1354-8. PubMed ID: 8912529
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase inhibitors.
Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.
Taraboletti G; Garofalo A; Belotti D; Drudis T; Borsotti P; Scanziani E; Brown PD; Giavazzi R
J Natl Cancer Inst; 1995 Feb; 87(4):293-8. PubMed ID: 7535861
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
[TBL] [Abstract][Full Text] [Related]
12. Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.
Favoulet P; Benoit L; Osmak L; Polycarpe E; Esquis P; Duvillard C; Guiu B; Rat P; Favre JP; Chauffert B
World J Surg; 2004 May; 28(5):451-6. PubMed ID: 15085402
[TBL] [Abstract][Full Text] [Related]
13. Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase.
Schwartz JD; Shamamian P; Monea S; Whiting D; Marcus SG; Galloway AC; Mignatti P
Surgery; 1998 Aug; 124(2):232-8. PubMed ID: 9706143
[TBL] [Abstract][Full Text] [Related]
14. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).
Eccles SA; Box GM; Court WJ; Bone EA; Thomas W; Brown PD
Cancer Res; 1996 Jun; 56(12):2815-22. PubMed ID: 8665519
[TBL] [Abstract][Full Text] [Related]
15. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
[TBL] [Abstract][Full Text] [Related]
17. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.
Tonn JC; Kerkau S; Hanke A; Bouterfa H; Mueller JG; Wagner S; Vince GH; Roosen K
Int J Cancer; 1999 Mar; 80(5):764-72. PubMed ID: 10048980
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
19. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model.
Lein M; Jung K; Le DK; Hasan T; Ortel B; Borchert D; Winkelmann B; Schnorr D; Loenings SA
Prostate; 2000 May; 43(2):77-82. PubMed ID: 10754522
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase inhibitors: a novel class of anticancer agents.
Brown PD
Adv Enzyme Regul; 1995; 35():293-301. PubMed ID: 7572350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
